 |
|
|
| |
Sofosbuvir/Velpatasvir for 12 Weeks in Patients
Coinfected With HCV and HIV-1: The ASTRAL-5 Study
|
| |
| |
Reported by Jules Levin
APASL Annual Meeting, February 15-19, 2017
Shanghai, China
Shyam Kottilil1, David Wyles2, Norbert Brau3,4, Eric Daar5, Kimberley Workowski6, Annie Luetkemeyer7, Oluwatoyin Adeyemi8, Peter Ruane9, Jina Lee10, Joseph Llewellyn10,Brian Doehle10, K.C. Huang10, Anu Osinusi10, John McNally10, Diana M. Brainard10, John G. McHutchison10, Susanna Naggie11, Mark Sulkowski12
1Institute of Human Virology, University of Maryland, Baltimore, Maryland, USA; 2Division of Infectious Diseases, University of California, San Diego, California, USA; 3Veteran Affairs Medical Center, New York, New York, USA; 4Icahn School of Medicine at Mount Sinai, New York, New York, USA; 5David Geffen School of Medicine, University of California, Los Angeles, California, USA; 6Emory University, Atlanta, Georgia, USA; 7University of California, San Francisco, California, USA; 8Rush University Medical Center, Chicago, Illinois, USA; 9Ruane Medical and Liver Health Institute, Los Angeles, California, USA; 10Gilead Sciences, Inc., Foster City, California, USA; 11Duke University, Durham, North Carolina, USA; 12Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
|
| |
|
|
|
|
|
